Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Artiva Biotherapeutics Inc (ARTV)

Artiva Biotherapeutics Inc (ARTV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 123,832
  • Shares Outstanding, K 24,717
  • Annual Sales, $ 0 K
  • Annual Income, $ -83,870 K
  • EBIT $ -90 M
  • EBITDA $ -87 M
  • 60-Month Beta 2.16
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.15

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate -0.88
  • Number of Estimates 3
  • High Estimate -0.86
  • Low Estimate -0.90
  • Prior Year -0.83
  • Growth Rate Est. (year over year) -6.02%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.74 +14.98%
on 03/27/26
7.75 -29.72%
on 03/11/26
-0.37 (-6.36%)
since 02/27/26
3-Month
3.62 +50.55%
on 02/09/26
7.75 -29.72%
on 03/11/26
+1.27 (+30.38%)
since 12/26/25
52-Week
1.47 +270.75%
on 06/27/25
7.75 -29.72%
on 03/11/26
+2.29 (+72.47%)
since 03/28/25

Most Recent Stories

More News
Artiva Biotherapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights

Initial clinical response data for AlloNK ® in refractory rheumatoid arthritis (RA) expected in first half of 2026 U.S. Food and Drug Administration (FDA) interaction to discuss potential pivotal...

ARTV : 5.45 (+8.78%)
Artiva Biotherapeutics to Participate in the TD Cowen 46th Annual Health Care Conference

SAN DIEGO, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies...

ARTV : 5.45 (+8.78%)
Artiva Biotherapeutics Announces Appointment of Thad Huston as Chief Financial Officer and Award of Inducement Grant

SAN DIEGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible...

ARTV : 5.45 (+8.78%)
Artiva Biotherapeutics Announces Appointment of Elaine Sorg to Board of Directors

SAN DIEGO, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible...

ARTV : 5.45 (+8.78%)
Artiva Biotherapeutics Announces Upcoming Presentations at the 2026 Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR® (Tandem Meetings) Highlighting Cost-Effectiveness of AlloNK in a Community Rheumatology Practice and Continued...

SAN DIEGO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible...

ARTV : 5.45 (+8.78%)
Artiva Biotherapeutics Announces Positive Initial Safety and Translational Data Supporting Deep B-Cell Depletion with AlloNK® in Autoimmune Disease

32 patients with autoimmune disease treated with AlloNK plus anti-CD20 monoclonal antibody (mAb) as of October 1, 2025, data cutoff All patients received AlloNK as outpatients, and the majority were...

ARTV : 5.45 (+8.78%)
Artiva Biotherapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Over 100 patients treated with AlloNK across autoimmune and oncology indications Refractory rheumatoid arthritis (RA) prioritized as lead indication following FDA Fast Track Designation for AlloNK®,...

ARTV : 5.45 (+8.78%)
Artiva Biotherapeutics to Host Virtual Event Discussing Initial Safety and Translational Data in up to 32 Patients with Autoimmune Disease Treated with AlloNK®

The virtual webcast will take place Wednesday, November 12, 2025, at 8 a.m. ET Initial safety data for 32 patients with autoimmune disease treated with AlloNK + monoclonal antibody (mAb) therapy,...

ARTV : 5.45 (+8.78%)
Artiva Biotherapeutics to Participate in Upcoming Investor Conferences in November

SAN DIEGO, Oct. 30, 2025 (GLOBE NEWSWIRE) --   Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies...

ARTV : 5.45 (+8.78%)
Artiva Biotherapeutics to Participate in the Cantor Global Healthcare Conference 2025

SAN DIEGO, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies...

ARTV : 5.45 (+8.78%)

Business Summary

Artiva Biotherapeutics Inc. is a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers. The company's lead program includes AlloNK(R). Artiva Biotherapeutics Inc. is based in SAN DIEGO....

See More

Key Turning Points

3rd Resistance Point 6.44
2nd Resistance Point 6.09
1st Resistance Point 5.77
Last Price 5.45
1st Support Level 5.10
2nd Support Level 4.75
3rd Support Level 4.43

See More

52-Week High 7.75
Last Price 5.45
Fibonacci 61.8% 5.35
Fibonacci 50% 4.61
Fibonacci 38.2% 3.87
52-Week Low 1.47

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.